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Abstract Target-specific oral anticoagulants have
become increasingly available as alternatives to traditional
agents for the management of a number of thromboembolic
disorders. To date, the direct Factor Xa inhibitor rivarox-
aban is the most widely approved of the new agents. The
dosing of rivaroxaban varies and adheres to specific
schedules in each of the clinical settings in which it has
been investigated. These regimens were devised based on
the results of phase II dose-finding studies and/or phar-
macokinetic modeling, and were demonstrated to be suc-
cessful in randomized, phase III studies. In most cases, the
pharmacodynamic profile of rivaroxaban permits once-
daily dosing. A once-daily dose is indicated for the pre-
vention of venous thromboembolism (VTE) in patients
undergoing hip or knee replacement surgery, the long-term
prevention of stroke in patients with non-valvular atrial
fibrillation, and the long-term secondary prevention of
recurrent VTE. Twice-daily dosing is required in the acute
phase of treatment in patients with VTE and in the com-
bination of rivaroxaban with standard single or dual anti-
platelet therapy for secondary prevention after acute
coronary syndrome events. This article reviews the
empirical and clinical rationale supporting the dose regi-
mens of rivaroxaban in each clinical setting.
1 Introduction
Hospital-based and outpatient-focused physicians are
increasingly prescribing target-specific oral anticoagulants
(TSOACs) as an alternative to traditional heparins and/or
vitamin K antagonists (VKAs) for the prophylaxis and
treatment of thromboembolic disorders. Rivaroxaban, da-
bigatran etexilate, and apixaban are all approved in Europe
and the United States for the prevention of stroke and
systemic embolism in patients with non-valvular atrial
fibrillation (AF) who are at risk of stroke [1–6]. All three
agents are also licensed in Europe for the prevention of
venous thromboembolism (VTE) after elective hip or knee
replacement surgery [1, 3, 5], and rivaroxaban and apix-
aban are approved for this indication in the United States
[2]. In addition, TSOACs are available in the United States
(dabigatran and rivaroxaban) and Europe (rivaroxaban
only) for the treatment of deep vein thrombosis (DVT) and
pulmonary embolism (PE), as well as for the secondary
prevention of VTE recurrence (Table 1) [1, 2]. In Europe,
rivaroxaban is approved for the prevention of athero-
thrombotic events in patients with recent acute coronary
syndrome (ACS) and elevated cardiac biomarkers, in
combination with standard antiplatelet therapy (Table 1)
[1].
The maintenance of vascular integrity amidst vessel wall
injury requires a complex interplay between the vascular
endothelium, platelets, and circulating proteins that either
promote (procoagulant) or limit (anticoagulant) the for-
mation of thrombosis. The successive activation of
procoagulant factors leading to thrombin generation is
recognized as the coagulation cascade, and results in the
conversion of soluble fibrinogen to insoluble fibrin, and the
formation of a stable thrombus (Fig. 1). Inhibition of the
coagulation cascade represents an important target in the
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management of various thromboembolic disorders. Tradi-
tional anticoagulants, such as unfractionated or low-
molecular-weight heparin (LMWH), target multiple points
in the coagulation cascade in concert with a cofactor.
VKAs, previously the only option for long-term oral
anticoagulation, do not directly target coagulation factors,
but lead to the synthesis of dysfunctional clotting Factors
II, VII, IX, and X [7]. TSOACs inhibit specific coagulation
factors: Factor Xa in the case of rivaroxaban apixaban, and
edoxaban and Factor IIa (thrombin) for dabigatran (without




Prevention of stroke and systemic embolism in
patients with atrial fibrillation at moderate to high
stroke riska




Ongoing provided the risk of stroke
outweighs the risk of bleedingb
Prevention of venous thromboembolism in patients
who have undergone major hip or knee
replacement surgery
10 mg od None 12–14 days after knee replacement
35 days after hip replacement
Treatment of deep vein thrombosis and pulmonary
embolism and prevention of recurrent venous
thromboembolism
15 mg bid for 3 weeks
(acute treatment)
20 mg od thereafter
(secondary prevention)
Nonec Generally at least 3 months but to
continue as long as the risk of recurrent
VTE outweighs the risk of bleedingd
Prevention of atherothrombotic events in patients
with recent acute coronary syndrome and
elevated cardiac biomarkers (Europe only)e




None Based on the individual patient’s risk of
ischemic events against bleeding risks
bid twice daily, CrCl creatinine clearance, od once daily
a CHA2DS2-VASc score recommended to assess stroke risk [80]
b HAS-BLED score may be useful for determining bleeding risk [80]
c No routine dose reduction but consider 15 mg od in patients with moderate renal impairment (CrCl 30–49 mL/min) with a high bleeding risk
(Europe only) [1]
d Clinical risk scores and risk factors for bleeding can be useful for assessment [49, 50]
e Cardiac biomarkers are troponin or creatinine kinase-MB [1]
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Factor IIIa
Fig. 1 Coagulation factors
targeted by the target-specific
oral anticoagulants
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the need for a cofactor; Fig. 1) [8]. Rivaroxaban, apixaban,
and edoxaban directly and selectively bind to the active site
of Factor Xa, regardless of whether it is freely circulating,
bound to the prothrombinase complex, or found within an
existing thrombus [9, 10]. Differences in the mechanism of
action of TSOACs compared with VKAs have important
implications for the management of these agents.
Rivaroxaban and the other TSOACs, apixaban, edox-
aban, and dabigatran, overcome many of the perceived
limitations of traditional anticoagulants. Unlike heparins,
they are taken orally, but have a comparably rapid onset of
action. Compared with warfarin and other VKAs, the
TSOACs have predictable pharmacokinetics and pharma-
codynamics that allow for fixed dosing (in the patient
populations studied to date), do not require routine coag-
ulation monitoring, and have fewer drug and food inter-
actions [8]. Despite these advantages, the long-term use of
TSOACs presents different challenges, including drug
accumulation in patients with renal dysfunction (varies by
drug), lack of an antidote or standardized reversal strategy
when life-threatening bleeding is encountered, and diffi-
culties in quantifying the degree of anticoagulation with
commonly available assays in emergency situations such as
urgent surgery (specific anti-Factor Xa assays, although
preferred, may not be routinely available or practical in
acute situations) [8]. As mentioned previously, predictable
dose–concentration response with TSOACs allows for
standard fixed dosing for various populations. Dosing for
TSOACs is based on phase II and III clinical trial data.
This represents a paradigm shift from the dosing of tradi-
tional anticoagulants that are typically titrated to specific
goals via coagulation assay monitoring.
Dosing in the various clinical settings for the TSOACs
takes into account many factors, including the specific
pharmacokinetics of each agent, the pharmacodynamic
effects observed (which may have a different timeline than
the clearance or half-life of the specific agent), decisions on
the acceptable peak-to-trough ratios observed with once-
daily or twice-daily dosing schemes, as well as the clinical
outcomes of different regimens tested in phase II and III
clinical trials. Specific dosing regimens for rivaroxaban are
approved for each clinical setting in which it is used. The
dosing regimens have been developed based on preclinical
data and clinical studies to take into account the balance of
antithrombotic efficacy and bleeding risk. In many clinical
scenarios, pharmacokinetic and pharmacodynamic data
support the use of once-daily rivaroxaban doses because its
antithrombotic effect persists for at least 24 hours for doses
above 5 mg [11]. In this review, the empirical and clinical
rationale supporting the dose regimens of rivaroxaban in
each clinical setting will be discussed, with consideration
of both the general populations and relevant special patient
groups.
2 Pharmacokinetic and Pharmacodynamic
Characteristics of Rivaroxaban in Healthy Subjects
and Specific Populations
2.1 Healthy Subjects
In phase I studies in healthy volunteers, rivaroxaban was
rapidly absorbed and demonstrated a high oral bioavail-
ability (Table 2) [11]. Maximum concentrations occurred
within a few hours of dosing and the half-life, which varied
by age, ranged between 5 and 9 hours in healthy young
subjects and from 11 to 13 hours in healthy elderly subjects
[11–13]. Rivaroxaban was the principal circulating drug and
no pharmacologically active metabolites were detected in
plasma [14]. Approximately two-thirds of a dose was found
to undergo metabolic degradation to inactive metabolites, of
which one third was eliminated renally and the other third
was eliminated via the hepatobiliary route; the final third
was excreted unchanged by renal filtration and renal secre-
tion (Table 2) [14, 15]. Rivaroxaban was well tolerated and
had predictable pharmacokinetics at different single and
multiple doses in healthy volunteers [11, 12, 16]. The
pharmacokinetics of rivaroxaban were not affected to a
clinically relevant degree by age [13, 17], gender [13, 17–
19], or body weight [18]. Pharmacokinetics were also sim-
ilar between Caucasian and Chinese subjects [19, 20].
Inhibition of Factor Xa activity was found to be dose-
dependent and correlated closely with rivaroxaban plasma
levels; the maximum effect occurred after approximately
3 hours and inhibition continued for at least 12 hours with
10-, 20-, and 30-mg twice-daily doses [12], and for more
than 24 hours with a 30-mg dose [21]. The effect on coag-
ulation assays also depended on dose [12]. The inhibition
constant of rivaroxaban (0.4 nM) [10] is equivalent to a
plasma concentration of unbound rivaroxaban of 0.17 lg/L,
which is typically exceeded even at trough concentrations
after 10- and 20-mg once-daily doses [10, 11, 21]. Through
population pharmacokinetic analysis the expected peak and
trough plasma concentrations for rivaroxaban in the treat-
ment of VTE are 270 lg/L (189–491 lg/L) and 26 lg/L
(6–87 lg/L), respectively. For atrial fibrillation the con-
current values are 249 lg/L (184–343 lg/mL) and 44 lg/L
(12–137 lg/L) [22]. Based on these data along with the
typical half-life in healthy and elderly patients of
11–13 hours (i.e., those in whom the drug persists longest)
[1, 2], anticoagulant effects would be expected to persist for
longer than 24 hours after these doses.
2.2 Renal and Hepatic Impairment
Exposure to rivaroxaban (area under the concentration–
time curve [AUC]) was increased by 44, 52, and 64 % in
patients with mild (creatinine clearance [CrCl] 50–79 mL/
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min), moderate (CrCl 30–49 mL/min), and severe (CrCl
\30 mL/min) renal impairment, respectively. However,
the peak concentration was less variable and the overall
effect, even for those with severe renal impairment, was
considered by the authors to be of moderate clinical rele-
vance only (Table 2) [23]. Nevertheless, clinical use of
rivaroxaban must take into account renal function, and
caution should be exercised in patients with moderate
(CrCl 30–49 mL/min) renal impairment. In Europe, riva-
roxaban may be used with caution in patients with severe
renal impairment (CrCl 15–29 mL/min); however, in the
United States rivaroxaban is not advised in these patients,
except in those with AF. In all cases, rivaroxaban should be
avoided in patients with a CrCl \15 mL/min [1, 2].
Mild (Child–Pugh A) hepatic impairment did not cause
a clinically relevant alteration of rivaroxaban pharmaco-
kinetics (15 % increase in AUC compared with healthy
subjects), but moderate impairment led to a marked
increase in exposure (Table 2) and pharmacodynamic
effects (159 % increase in the effect–time curve AUC and
significant prolongation of prothrombin time) [24]. As
such, rivaroxaban therapy is not recommended in patients
with moderate to severe hepatic impairment, including
hepatic disease associated with coagulopathy and clinically
relevant bleeding risk, and in cirrhotic patients (Child–
Pugh B and C) [1, 2].
2.3 Food Effects and Drug–Drug Interactions
Oral bioavailability was high (80–100 %) for a 10-mg dose
regardless of food intake, but at higher doses of 15 or
20 mg in the absence of food, bioavailability and absorp-
tion rate were less than dose proportional [16, 25]. Without
food, the bioavailability of a 20-mg dose of rivaroxaban
was 66 % and the AUC was 1,447 lgh/L. When this dose
was given with food, the bioavailability was nearly 100 %
with a 39 % increase in the AUC (2,048 lgh/L) (Table 2)
[26]. Therefore, while taking rivaroxaban with food is
necessary for optimal absorption, if food could not be
administered for a single day due to the patient being NPO
(nil by mouth), there is still about two thirds of the dose
absorbed. Clinicians need to weigh the potential clinical
impact of this change in absorption. The decreased
absorption rate appears to be due to the limited aqueous
solubility of rivaroxaban at higher doses, leading to a lower
absolute oral bioavailability for the 20-mg tablet under
fasting conditions compared with fed conditions [26].
Rivaroxaban absorption was unaffected by changes in
gastric pH due to ranitidine or antacid use [25], and
pharmacokinetics were unaltered by digoxin or atorvastatin
[27]. Concomitant administration of other anticoagulants,
non-steroidal anti-inflammatory drugs, or antiplatelet
agents may increase bleeding risks, and potential interac-
tions of rivaroxaban with these agents have been investi-
gated in phase I studies. Co-administration with enoxaparin
did not affect pharmacokinetics but led to an additive effect
on anti-Factor Xa inhibition [28]. Co-administration of
naproxen with rivaroxaban did not prolong bleeding time
to a clinically relevant extent, but there was evidence of a
more pronounced response in some individuals [29]. When
co-administered with antiplatelet agents, the bioavailability
and pharmacokinetics of a 15-mg dose of rivaroxaban were
























64 % higher 127 % higher 39 % higher Approximately 150 % higher
Maximum
concentration (ng/mL)
141a–173b 35 % higher 27 % higher 76 % higher 53–72 % higher
Time to maximum
concentration (h)
2–4 Similar to control Similar to control Not given Similar to control
Apparent half-life (h) 5–9 (young),
11–13
(elderly)
Similar to control Similar to control Not given Similar to control
Severe renal impairment corresponded to a creatinine clearance of \30 mL/min; moderate hepatic impairment corresponded to Child–Pugh B
CYP cytochrome P450, P-gp P-glycoprotein
a 10 mg oral dose
b 20 mg oral dose
c Taking 15 and 20 mg doses with food corrects pharmacokinetic parameters
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not affected by steady-state clopidogrel, although bleeding
time increased to a clinically relevant extent [30]. No
clinically relevant pharmacokinetic or pharmacodynamic
effects occurred with the combination of rivaroxaban and
acetylsalicylic acid (ASA; 500 mg loading dose then
100 mg the next day plus rivaroxaban 15 mg) [31]. Riva-
roxaban is eliminated by multiple pathways, which include,
among others, metabolic degradation by cytochrome P450
3A4 (CYP3A4) and it is a substrate for P-glycoprotein (P-
gp)-dependent pathways [15, 32], and a relevant increase in
rivaroxaban exposure was seen with co-administration of
strong inhibitors of both CYP3A4 and P-gp (e.g., keto-
conazole, ritonavir; Table 2) [1, 2, 15]. Because of the
multiple routes of elimination, drugs that inhibit only one of
these pathways and those that moderately inhibit both
pathways did not have a clinically relevant effect on the
pharmacokinetics of rivaroxaban. However, care must be
taken with concomitant administration of moderate inhibi-
tors in the setting of patients with chronic kidney disease
(CrCl 30–49 mL/min) because the risk of bleeding may be
increased [1, 2]. CYP3A4 inducers (e.g., rifampicin) have
the potential to reduce rivaroxaban plasma concentrations
to a significant degree, and concomitant therapy is not
recommended because of the risk of reduced efficacy [1, 2].
3 Prevention of Venous Thromboembolism in Patients
Undergoing Elective Hip or Knee Replacement
Surgery
Patients undergoing major orthopedic surgery to replace
hip or knee joints have an incidence of VTE of approxi-
mately 40–60 % if no thromboprophylaxis is given [33].
As per international guidelines, acceptable options to
reduce the risk of VTE include parenteral anticoagulation
with unfractionated heparin, LMWH, or fondaparinux, or
oral antithrombotic therapy with ASA, warfarin, or a
TSOAC. Depending on the agent selected, therapy is
started around the time of surgery and continued for
2–6 weeks [34]. Although a lower-grade recommendation,
LMWH therapy is still considered the preferred option
given the amount of evidence available [34]. However, in
patients given parenteral agents, high rates of non-adher-
ence to the recommended duration of anticoagulation have
been reported, owing partly to the burden of self-injection
[35]. Rivaroxaban has a similarly rapid onset of action to
the commonly used LMWH enoxaparin [28], which is
important in this setting, and could be more convenient for
patients (particularly after discharge) because of its once-
daily administration and oral rather than injectable
formulation.
Rivaroxaban was initially evaluated in patients under-
going total hip and knee replacement surgery in a series of
four phase II dose-finding studies. Rivaroxaban doses
ranging from 2.5 to 30 mg twice daily or from 5 to 40 mg
once daily, starting 6–8 hours after surgery, were compared
with standard enoxaparin prophylactic doses (30 mg twice
daily [bid] or 40 mg once daily [od]). Bilateral venography
was performed between 5 and 9 days after surgery to verify
the incidence of VTE, and bleeding outcomes were
recorded [36–39]. Empirical analysis of the results of the
four studies taken together suggested that rivaroxaban
doses, in the range of 5–20 mg daily, had a comparable
efficacy and safety profile to enoxaparin. As expected,
lower daily doses were associated with a greater incidence
of VTE, whereas higher doses led to an increased incidence
of major bleeding. Overall, a 10 mg once-daily dose of
rivaroxaban appeared to offer the potential for superior
VTE prevention compared with enoxaparin 40 mg once
daily and a similar incidence of major bleeding (Fig. 2)
[36–39]. Further support to continue the 10-mg once-daily
dose into phase III clinical trials came from previous pre-
clinical work demonstrating that reasonable anti-Factor Xa
activity was still present at 24 hours, indicating that
patients would receive adequate levels of anticoagulation
throughout the dosing interval (Fig. 3) [11].
Data from these trials were used to construct two pop-
ulation pharmacokinetic and pharmacodynamic models,
one of which compared once- and twice-daily doses in
patients undergoing hip replacement surgery [40], and the
other also included patients undergoing knee replacement
surgery [41]. The models were used to simulate the effect
of different dosing regimens, variations in population
demographic factors, and the effect of co-medications. In
the first model, the peak plasma concentration with a
10-mg once-daily dose was similar to that in healthy vol-
unteers (median 125 vs 141 ng/mL) [11, 40], and trough
concentrations between doses (*9 lg/L) were not signif-
icantly different from those with 5-mg twice-daily dosing,
further supporting the use of a once-daily dose [40]. The
average effect of variations in body weight, age, renal
function, and other factors remained within the variability
of the overall population, indicating that rivaroxaban could
be given at a fixed dose to a variety of patients undergoing
hip replacement surgery [40]. Even when extreme scenar-
ios were simulated (age 90 years, moderate-to-severe renal
impairment [CrCl 30 mL/min], low body weight [40 kg],
and combined age of 90 years and body weight of 40 kg),
the plasma concentration–time profiles of rivaroxaban
remained within the predicted 90 % confidence intervals
for the average population (Fig. 4). In the second model, in
which patients undergoing knee replacement surgery were
also included, the only relevant difference in pharmacoki-
netics between hip and knee replacement surgery patients
was a 26 % lower drug clearance, which led to an
approximately 30 % greater exposure to rivaroxaban [41].
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The 10-mg once-daily dose was taken forward to four
phase III clinical studies in the RECORD (REgulation of
Coagulation in ORthopedic Surgery to Prevent DVT and
PE) program, in which more than 12,500 patients were
randomized to receive rivaroxaban 10 mg once daily star-
ted 6–8 hours after surgery, or enoxaparin started before
(40 mg once daily) or after (30 mg twice daily) surgery
[42]. In patients undergoing total hip replacement surgery,
rivaroxaban given for 5 weeks was compared with enox-
aparin 40 mg once daily given for 5 weeks (RECORD1
[43]) or 2 weeks (RECORD2 [44]). In patients undergoing
total knee replacement surgery, rivaroxaban was compared
with enoxaparin 40 mg once daily (RECORD3 [45]) and
enoxaparin 30 mg twice daily (RECORD4 [46]), with all
regimens given for 2 weeks. A variety of comparisons
were thus possible, including the effect of longer compared
with shorter duration thromboprophylaxis (RECORD2),
and the efficacy and safety of rivaroxaban against the en-
oxaparin regimens most commonly used in Europe
(RECORD1–3) and North America (RECORD4). In all
trials, rivaroxaban was superior to enoxaparin for the pre-
vention of VTE and there was no significant increase in
major bleeding. In a pooled analysis of all the trials com-
paring rivaroxaban with enoxaparin 40 mg once daily
(RECORD1–3; n = 9,581), rivaroxaban significantly
reduced the incidence of VTE plus all-cause mortality
(Table 3). The incidence of major bleeding was similar
between the treatments at these time points [47]. When the
trial of rivaroxaban compared with enoxaparin 30 mg twice
daily (RECORD4; n = 12,729) was included in a pooled
analysis of all four RECORD trials, rivaroxaban was
associated with a significantly lower incidence of symp-
tomatic VTE plus all-cause mortality than enoxaparin on












































)Fig. 2 Composite efficacy and
safety profile of different
rivaroxaban doses compared
with enoxaparin for the
prevention of VTE after hip and
knee replacement surgery in
four phase II dose-finding
studies [36–39]. Doses for
which rivaroxaban bars
remained below the line
performed better overall than
enoxaparin 40 mg od. The
composite outcome depicted
here was not a predefined
endpoint of these trials. bid
twice daily, od once daily, VTE
venous thromboembolism
Fig. 3 Median percentage
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between treatments in terms of major bleeding, major plus
non-major clinically relevant bleeding, or any bleeding
[42]. Confirming the earlier studies, fixed-dose, oral riva-
roxaban 10 mg once daily was found to have improved
efficacy and similar safety to injectable enoxaparin across
patient subgroups in this indication.
4 Treatment of Deep Vein Thrombosis and Pulmonary
Embolism, and Prevention of Recurrent Venous
Thromboembolism
Venous thromboembolism, comprising DVT and PE, is an
established public health concern and is estimated to be
responsible for almost half a million deaths in the European
Union and approximately 300,000 fatalities in the United
States annually [48, 49]. The standard treatment approach
for all patients with VTE (specifically proximal DVT and
PE, management of calf vein DVT is less established and
varies by global region) includes therapeutic anticoagula-
tion, and for patients not considered at high risk of
immediate death, treatment usually starts with a parenteral
anticoagulant such as a LMWH. An oral VKA is then
added in parallel and the parenteral drug is discontinued
after a minimum of 5 days of concomitant therapy and
once the international normalized ratio (INR) is stable
within the target range of 2.0–3.0 [50, 51]. All patients
should receive a minimum of 3 months of therapeutic
anticoagulation for the management of proximal DVT or
PE, and many patients are candidates for longer durations
of therapy to prevent recurrent events [50, 51]. This dual-
drug paradigm (parenteral agent plus VKA) has been
demonstrated to be very effective, but requires careful
management, with patients subject to regular coagulation
monitoring for the duration of their VKA treatment to keep
the INR within the target range. By contrast, oral riva-
roxaban can be used alone from the outset of treatment
without the need for routine coagulation monitoring.
Two phase II studies were conducted to test the proof of
concept of rivaroxaban as a single drug approach to treat
VTE as compared with the standard approach of injectable
anticoagulant plus vitamin K antagonist (VKA). Data from
both trials were used to help determine an appropriate
rivaroxaban dosing schedule for VTE treatment in phase III
testing. The first trial evaluated single daily doses of riv-
aroxaban 20, 30, or 40 mg on asymptomatic deterioration
in thrombotic burden or symptomatic VTE compared with
LMWH plus VKA [52]. The companion trial evaluated
dosing regimens of 10, 20, or 30 mg twice daily as well as
40 mg once daily compared with standard LMWH plus
VKA on improvement in thrombotic burden at 21 days
without recurrent symptomatic VTE or VTE-related death
[53]. In the latter trial, no significant difference was
observed in the dose–response relationship between twice-
daily rivaroxaban doses and the primary endpoint. How-
ever, it was noted that patients receiving the 40-mg once-
daily dose had fewer patients with improvement in
thrombus burden at 21 days (43.8 %) compared with
twice-daily regimens (53–59.2 %) (Fig. 5a). The 10- and
20-mg twice-daily rivaroxaban regimens had fewer cases
of major bleeding than the 30-mg twice-daily dose.
In the trial evaluating once-daily doses over the course
of 3 months, the 20-, 30-, and 40-mg once-daily rivarox-
aban regimens compared favorably with standard therapy
in terms of reducing thrombus burden, with a similar
incidence of major bleeding (Fig. 5b). Based on the
Fig. 4 Simulations of mean
rivaroxaban plasma
concentrations after a 10-mg
once-daily dose in patients who
have undergone hip replacement
surgery (with permission [40]).
Patients who are elderly, have
moderate-to-severe renal
impairment, have low body
weight, or are elderly with low
body weight, have predicted
average plasma concentrations
that fall within the boundaries
for the overall population (90 %
confidence intervals). CrCl
creatinine clearance
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outcomes of these two studies, the lowest effective daily
dose for rivaroxaban in the treatment of VTE was identified
as 20 mg daily. In addition, phase II results also raised the
possibility that an initial twice-daily regimen may provide
better clot resolution during the first 21 days of therapy.
Utilization of a higher dose during initial therapy is also
supported by other VTE trials that have shown that the
highest risk of recurrent VTE occurs in the acute phase
(initial 3–4 weeks) of treatment [54, 55]. Taking these
considerations together, the EINSTEIN investigators chose
a 15-mg twice-daily dose for 21 days, followed by transi-
tion to a 20-mg once-daily dose for the duration of therapy
[56–58]. The EINSTEIN investigators did not discuss their
selection of the 15 mg twice-daily dose in their methods
paper as it was not studied in phase II testing [58]. How-
ever, we might speculate they simply picked a dose
between the 10- and 20-mg twice-daily dosing regimens
that offered efficacy with the lowest risk of bleeding.
The proposed two-step dose regimen for rivaroxaban of
15 mg twice daily for 3 weeks followed by 20 mg once
daily was evaluated using pharmacokinetic data from 870
patients with acute DVT in the phase II studies to create a
population model and provide more information on the
transition between once- and twice-daily dosing as required
by the rivaroxaban VTE treatment regimen [56]. The
model showed that age and renal function had a moderate
effect on the pharmacokinetics of rivaroxaban, but varia-
tions remained minimal from the overall population. As
such, no dose adjustment for patient populations who might
be at risk for drug accumulation (renal dysfunction,
extremes in body weight, age, etc.) was utilized in phase III
testing for VTE. Simulations predicted a consistent expo-
sure (i.e., no substantial changes in maximum concentra-
tion) to rivaroxaban during the transition from 15-mg
twice-daily to 20-mg once-daily dosing (Fig. 6). Although
the rivaroxaban AUC increased in a dose-dependent fash-
ion with both once- and twice-daily dosing, the AUC
results obtained for both regimens were similar. When
comparing the same total daily doses, the peak plasma
concentration was approximately 20 % higher and the
trough concentration was approximately 60 % lower with
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Fig. 5 Composite efficacy and
safety profile of different
rivaroxaban doses compared
with enoxaparin/VKA for the
treatment of deep vein
thrombosis in two phase II dose-
finding studies. a 21-day
thrombus regression and major
bleeding; b 3-month thrombus
burden and clinically relevant
bleeding [52, 53]. Rivaroxaban
bars that remained below the
line performed better overall
than enoxaparin/VKA.
Clinically relevant bleeding was
the composite of major and non-
major clinically relevant
bleeding. The composite
outcome depicted here was not a
pre-defined endpoint of these
trials. bid twice daily, od once
daily, VKA vitamin K antagonist
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Because the 5th–95th percentile ranges for these parame-
ters had substantial overlap, once-daily dosing should not
expose patients to a greater risk of bleeding at the peak
plasma concentration, or thrombus growth at the trough
plasma concentration) compared with twice-daily dosing
[56]. The model also demonstrated that significant plasma
concentrations of rivaroxaban, expected to provide an
adequate anticoagulant effect, would be present at the end
of the 24-hour dosing interval during long-term therapy
with a once-daily dose [56].
Two phase III studies of rivaroxaban for acute VTE
treatment were conducted [57, 59]. EINSTEIN DVT
recruited patients with symptomatic, confirmed DVT
without PE [57], whereas EINSTEIN PE included patients
with PE with or without concurrent DVT [59]. PE was
studied separately because it has a distinct clinical course
to DVT and is also less common; therefore, trials involving
a general VTE population may not recruit a sufficient
proportion of patients with PE to confirm outcomes in this
group. Both trials followed the same design, with patients
randomized to receive 3, 6, or 12 months of treatment with
rivaroxaban 15 mg twice daily for 3 weeks followed by
20 mg once daily, or enoxaparin 1 mg/kg twice daily
overlapping with and transitioning to a VKA (warfarin or
acenocoumarol) with the dose adjusted to maintain an INR
of 2.0–3.0 [57, 59].
In EINSTEIN PE, the first 400 patients included in the
study were evaluated separately to confirm that the dose
regimen, which had been selected based on outcomes in
patients with symptomatic DVT without symptomatic PE,
was efficacious and safe for patients with PE. Based on the
incidence of the composite of symptomatic recurrent VTE
and asymptomatic deterioration on repeat lung imaging at
3 weeks, the regimen was deemed to be appropriate [59].
In both EINSTEIN DVT and EINSTEIN PE, rivaroxaban
was non-inferior to enoxaparin/VKA for the prevention of
recurrent, symptomatic VTE (Table 3). There was also no
difference between the regimens in the incidence of major
plus non-major clinically relevant bleeding [57, 59].
However, in EINSTEIN PE, rivaroxaban provided a 51 %
relative risk reduction in the incidence of major bleeding
(Table 3). Outcomes were consistent in subpopulations of
patients such as the elderly, those with renal impairment,
and patients with high or low body weight, suggesting that
the rivaroxaban regimen would be appropriate without the
need for adjustment in this setting. It is important to note
that patients with an estimated CrCl \30 mL/min were
excluded from the EINSTEIN trials, and that patients
receiving thrombolytic therapy were also excluded from
the EINSTEIN PE trial [57, 59]. An extension study of
long-term rivaroxaban treatment to prevent recurrent VTE,
EINSTEIN EXT, was also conducted. Patients who had
been successfully treated for an initial VTE, but for whom
the decision to continue or stop anticoagulation was
uncertain, received either rivaroxaban 20 mg once daily or
placebo for a further 6 or 12 months [57]. Rivaroxaban was
superior to placebo for the prevention of recurrent VTE,
without a significant increase in major bleeding (Table 3)
[57].
5 Prevention of Stroke and Systemic Embolism
in Patients with Non-Valvular Atrial Fibrillation
AF is the most common dysrhythmia that occurs in clinical
practice and is responsible for approximately 500,000
hospitalizations in the United States alone [60]. Conser-
vative estimates suggest that 2.7 million patients in the
United States and 4.5 million in the European Union have
AF [60, 61]. These numbers are expected to at least double
in the next 30 years because of the aging population [62].
Patients with AF have an approximately five-fold increase
in the risk of stroke compared with the general population
[63]. Patients with AF are routinely prescribed oral anti-
coagulant therapy such as warfarin or another VKA. The
limitations of VKA therapy have been well described, and
the use of an oral anticoagulant that does not require dose
adjustment (fixed dose) or lifetime therapeutic monitoring
would be a significant advantage in the management of
these patients. Whereas dabigatran and apixaban are both
administered twice daily for the reduction of risk of stroke
in patients with AF, rivaroxaban is taken once daily. This
adds to the simplicity of the regimen and may improve
adherence [64].
The once-daily dosing of rivaroxaban that has been
investigated to reduce the risk of stroke in patients with AF
was developed from a population pharmacokinetic model
[56]. This model used data on rivaroxaban
Study day



























Fig. 6 Simulated venous thromboembolism treatment dosing regi-
men of rivaroxaban 15 mg bid for 3 weeks, followed by 20 mg od
(with permission [56]). Rivaroxaban exposure remains consistent
during the transition, indicating that antithrombotic activity should be
maintained. bid twice daily, od once daily
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pharmacokinetics from the two previously described phase
II studies of patients treated for DVT [52, 53]. The purpose
of this modeling study was to simulate the pharmacoki-
netics of rivaroxaban in a virtual patient population with
AF, and thus DVT treatment population data were modified
to reflect the demographic characteristics of a patient
population with AF [56]. The demographic data used to
represent this typical AF population came from the
SPORTIF (Stroke Prevention Using Oral Thrombin
Inhibitor in Atrial Fibrillation) III and V trials of patients
with AF [65, 66]. Simulations were conducted to determine
which demographic factors influenced the rivaroxaban
exposure in AF patients [56]. The results of these simula-
tions determined that moderate renal impairment (CrCl
30–49 mL/min), and, to a lesser extent, age C75 years, led
to a slight increase in rivaroxaban exposure. The simulated
plasma concentration–time profile for patients with normal
renal function receiving rivaroxaban 20 mg once daily was
similar for simulated AF and DVT patients. Additionally,
the increase in rivaroxaban exposure because of decreased
renal function in this simulation was corrected by dose
adjustment to 15 mg once daily (Fig. 7) [56]. Therefore,
for phase III clinical testing, the 20-mg once-daily dose
was chosen for patients with normal renal function, and the
15-mg once-daily dose was chosen for patients with
moderate renal insufficiency.
The suitability of the aforementioned dose was con-
firmed in the randomized, double-blind, double-dummy,
phase III trial, ROCKET AF (Rivaroxaban Once-daily Oral
Direct Factor Xa Inhibition Compared with Vitamin K
Antagonism for Prevention of Stroke and Embolism Trial
in Atrial Fibrillation) [67]. A total of 14,264 patients with
non-valvular AF at moderate to high risk of stroke were
randomized to rivaroxaban, dosed as above, or dose-
adjusted warfarin (managed to an INR of 2.0–3.0). In the
intention-to-treat analysis, the primary endpoint of stroke
or systemic embolism occurred at a rate of 2.1 % per year
in patients receiving rivaroxaban and 2.4 % per year in
patients receiving warfarin. This 12.5 % relative risk
reduction with rivaroxaban met the criteria for non-inferi-
ority (p \ 0.001), but not superiority (p = 0.12). The pri-
mary analysis of the trial was designed to be the per-
protocol, as-treated population. In this group, a benefit of
rivaroxaban was demonstrated compared with warfarin
(hazard ratio 0.79; 95 % CI 0.66–0.96; Table 3). Among
patients in the on-treatment safety population, rivaroxaban
was superior to warfarin (p = 0.01). Rates of clinically
relevant bleeding and major bleeding were similar between
the treatment arms (Table 3). However, rivaroxaban use
led to a significant decrease in intracranial hemorrhage
(p = 0.02) and fatal bleeding (p = 0.003), although the
incidence of gastrointestinal bleeding was higher in the
rivaroxaban arm (p \ 0.001) [67]. Pharmacokinetic ana-
lysis of 161 patients in ROCKET AF supported the pre-
dictions of the modeling work, and confirmed that
parameters for patients with moderate renal impairment
(who were given rivaroxaban 15 mg once daily) were
similar to those with normal renal function who received
20 mg twice daily [68]. Therefore, ROCKET AF demon-
strated that rivaroxaban provides comparable efficacy to
warfarin, with less intracranial and fatal bleeding at a cost
of more gastrointestinal bleeding.
6 Prevention of Cardiovascular Events in Patients
with Recent Acute Coronary Syndrome
An ACS event is a common complication of coronary heart
disease and is associated with more than 1.2 million hos-
pitalizations in the United States and close to 3 million






























20 mg od, patients with CLCR >50 mL/min
15 mg od, patients with CLCR ≤50 mL/min
Fig. 7 Simulated rivaroxaban
plasma concentration–time
profiles for a virtual population
of patients with atrial fibrillation
(with permission [56]). For
patients with mildly impaired or
normal CrCl ([50 mL/min),
exposure is the same with a
20 mg od dose as for patients
with moderate renal impairment
(B50 mL/min) with a 15 mg od
dose. CrCl creatinine clearance,
od once daily
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hospitalizations worldwide annually [60, 69]. ACS com-
prises unstable angina (UA), non-ST-segment elevation
myocardial infarction (NSTEMI), and ST-elevation myo-
cardial infarction (STEMI), with UA and NSTEMI com-
monly grouped together as non-ST-segment elevation ACS
(NSTE ACS). Standard chronic management of patients
who have had an ACS event includes treatment with dual
antiplatelet therapy consisting of ASA and a P2Y12 inhib-
itor. Despite this aggressive antiplatelet strategy, the rate of
recurrent cardiovascular events remains high (*10 %) [70,
71]. There is evidence of sustained coagulation activation
after an ACS event [72, 73], and previous studies have
shown that the addition of an oral anticoagulant (e.g.,
warfarin) to antiplatelet therapy can further reduce recur-
rent cardiovascular events but increases the risk of bleeding
[74, 75].
The phase II dose-ranging study ATLAS ACS TIMI 46
(Anti-Xa Therapy to Lower Cardiovascular Events in
Addition to Standard Therapy in Subjects With Acute
Coronary Syndrome ACS 2–Thrombolysis In Myocardial
Infarction 46: Rivaroxaban Versus Placebo in Patients with
Acute Coronary Syndromes) was conducted in patients
who had experienced a recent ACS event [76]. Patients
were randomized to receive rivaroxaban at doses of 5, 10,
or 20 mg once daily or the same total doses twice daily, or
equivalent placebo, in addition to single or dual antiplatelet
therapy (depending on the decision of the individual
investigator). Rivaroxaban reduced the incidence of death,
MI, or stroke, but increased the risk of clinically significant
bleeding dose-dependently [76]. Overall, doses of 2.5 and
5 mg twice daily appeared to offer the best balance of
efficacy and safety (Fig. 8), and these were selected for
further investigation. These doses of rivaroxaban are much
lower than those used in stroke prevention in atrial
fibrillation and in the treatment of VTE. While coagulation
plays a role in thrombosis in the arterial vascular, most of
the process is dominated by platelets. Therefore, in com-
bination with single or dual antiplatelet therapy, it is likely
that less intense long-term anticoagulation would be opti-
mal. Data from 2,290 patients with pharmacokinetic values
from the ATLAS ACS TIMI 46 trial were entered into a
population pharmacokinetic model. The data indicated that
pharmacokinetic parameters, and the effects of factors such
as age, renal function, and body weight, would be similar
for patients with ACS receiving rivaroxaban 2.5 mg twice
daily as for the other population models in patients
receiving rivaroxaban for VTE prevention, VTE treatment,
and for stroke prevention in patients with AF [77].
In the randomized phase III ATLAS ACS 2 TIMI 51
study, rivaroxaban 2.5 or 5 mg twice daily added to stan-
dard antiplatelet therapy (ASA ± a thienopyridine) was
assessed against antiplatelets alone in patients with a recent
ACS event [78]. The addition of rivaroxaban at either dose
significantly reduced the incidence of death from cardio-
vascular causes, MI, or stroke (Table 3) but, unlike the
higher dose, the 2.5-mg twice-daily dose led to signifi-
cantly reduced rates of death from cardiovascular causes
(p = 0.002) and any cause (p = 0.002). Rivaroxaban was
associated with an increased incidence of major bleeding
not related to coronary artery bypass grafting (1.8 % for the
2.5-mg dose and 2.4 % for the 5-mg bid dose vs 0.6 %;
p \ 0.001 for both rivaroxaban doses combined vs pla-
cebo) and intracranial bleeding (0.4 % for the 2.5-mg bid
dose and 0.7 % for the 5-mg bid dose vs 0.2 %; p = 0.009
for both rivaroxaban doses combined vs placebo), but fatal
bleeding was not increased (0.3 vs 0.2 %; p = 0.66). The
lower dose resulted in a lower rate of fatal bleeding than
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Fig. 8 Composite efficacy and safety of different doses of rivarox-
aban compared with placebo, both combined with standard antiplate-
let therapy, for the prevention of recurrent events in patients with
ACS in a phase II dose-finding study [76]. Clinically relevant
bleeding was the composite of major and non-major clinically
relevant bleeding. The composite outcome depicted here was not a
pre-defined endpoint of this trial. ACS acute coronary syndrome, bid
twice daily, od once daily
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these data, the 2.5-mg twice-daily dose was approved in
Europe as an adjunct to antiplatelet therapy, but only in
patients with a recent ACS event and elevated cardiac
biomarkers, suggesting a high likelihood of recurrence.
Rivaroxaban is currently not approved in the United States
for this indication, as the FDA has raised concerns with
trial results and data management.
7 Implications for Daily Clinical Practice
The rivaroxaban clinical study program, including phase I
pharmacokinetic and pharmacodynamic investigations,
phase II dose-finding studies, and randomized phase III
clinical trials, as well as pharmacokinetic modeling and
simulation work, provide a body of evidence to support the
doses that are now used in each approved clinical indica-
tion (Table 1). Despite a half-life that would suggest the
need for twice-daily dosing (5–9 h in healthy young sub-
jects, 11–13 h in healthy elderly patients), once-daily doses
are appropriate in many situations based on positive results
from phase II and III clinical trials for patients with AF,
patients who have undergone hip or knee replacement
surgery, and those receiving long-term treatment for the
prevention of recurrent VTE. In addition, it is important to
consider that similar to what has been observed for
LMWHs, the pharmacodynamic effects for rivaroxaban
exceed the pharmacokinetic half-life. As such, the duration
of pharmacodynamic effect (anti-Xa activity) should be the
main determinant of the daily dosing schedule. Neverthe-
less, it is important to consider clinical circumstances in
which daily dosing is not the case, namely the initial
3 weeks of twice-daily rivaroxaban treatment for acute
DVT or PE and for patients with ACS; (Table 1). The
clinical pharmacology of rivaroxaban supports a once-daily
dosing regimen for VTE prophylaxis after hip and knee
replacement surgery (10 mg) and the prevention of recur-
rent VTE and stroke (20 mg) because of a long-lasting
effect on thrombin generation and trough plasma drug
concentrations sufficient to provide an effective anti-
thrombotic effect for 24 hours or longer [10, 11, 21, 40,
56].
Routine dose reduction for renal impairment is recom-
mended at this time only for patients with AF who are
receiving rivaroxaban for stroke prevention and who have
moderate (CrCl 30–49 mL/min) or severe (CrCl
15–29 mL/min) renal impairment. In these patients, a
15-mg once-daily dose is recommended instead of the
normal 20-mg once-daily dose [1, 2]. This dose reduction
was as effective as standard therapy when clinically tested
in patients with renal impairment in ROCKET AF [67]. By
contrast, patients receiving rivaroxaban for long-term sec-
ondary prevention of recurrent VTE, for whom the same
20-mg once-daily dose is recommended, should not rou-
tinely be given a reduced dose if they have renal impair-
ment (CrCl 15–50 mL/min), as they did not receive such a
dose in the phase III EINSTEIN trials [57, 59]. The
rationale is that VTE patient populations are generally
younger and have fewer co-morbidities than AF popula-
tions and are, therefore, less susceptible to drug accumu-
lation. As previously stated, pharmacokinetic modeling for
this patient population did not indicate a large variation in
plasma concentrations accompanying changes in either age
or renal function [56]. In addition, clinical trial results
support this approach. In a combined pooled analysis of
both the EINSTEIN DVT and PE trials, it was found that in
patients with a calculated creatinine clearance \50 mL/
min, rivaroxaban demonstrated a lower risk of bleeding as
compared with patients receiving LMWH/warfarin with a
similar effect on efficacy. Similar favorable results with
safety were also seen in patients[75 years of age, or who
weighed less than 60 kg. These results further support
maintaining patients at a dose of 20 mg once daily down to
a creatinine clearance of 30 mL/min [79]. Although these
results stem from a secondary analysis of the EINSTEIN
trials, it is important to note that the subpopulation for
reduced renal function totaled 649 patients, a sample size
that is far larger than exists for any other anticoagulant in
this patient population. Regardless, the European Summary
of Product Characteristics states that a 15-mg once-daily
dose may be considered in patients receiving long-term
rivaroxaban for prevention of secondary VTE if the risk of
bleeding is high and outweighs the evaluated risk for
recurrent VTE [1]. However, this recommendation is not
included in the US Prescribing Information [2]. In general,
with the exception of ROCKET AF, few of the dose
reductions recommended for TSOACs have actually been
tested in clinical trials. It is important that patients with a
CrCl \15 min/mL should not receive rivaroxaban for any
of the approved indications because of the risk of drug
accumulation.
Rivaroxaban is appropriate for a broad population of
patients because its pharmacokinetic and pharmacody-
namic properties generally do not vary to a clinically rel-
evant degree with variations in gender, age, body weight,
ethnicity, and mild or moderate renal and mild hepatic
impairment [39, 56, 77]. However, there are circumstances
and patient groups in which these agents are either not
appropriate or relatively untested. Critically ill patients
with PE who have shock and/or hypotension and require
urgent thrombolytic therapy or thromboectomy fall into
this category, and there are no data on the use of TSOACs
in this setting. There are also no data on the use of these
drugs during pregnancy, in patients aged \18 years, or in
patients with a CrCl \15 mL/min; therefore, use of riva-
roxaban is not recommended in these patients [1, 2]. Use in
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patients with moderate or severe hepatic disease (Child–
Pugh B or C) is also not recommended because of a clin-
ically relevant increased risk of bleeding. In general, more
data are needed in patients with moderate renal impairment
and those with cancer, relatively few of whom have been
included in the phase III trials of the TSOACs, and also in
patients with severe renal impairment (CrCl 15–29 mL/
min), who were excluded from phase III studies because of
their high bleeding risk. Although risk of major bleeding
appears to be comparable to other anticoagulants, it is
important to note that a small number of patients on riva-
roxaban will experience a bleeding event and further
guidance is needed with regards to effective reversal
strategies in the case where bleeding may be life-
threatening.
Rivaroxaban is increasingly used by clinicians in a
broad range of thromboembolic disorders. Use of the spe-
cific dose regimen for each indication is vital to optimize
therapeutic benefit and minimize risk of bleeding.
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